# Mineralys Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mineralys-therapeutics

- Industry: Biotechnology
- Headquarters: Radnor, US
- Website: www.mineralystx.com
- Total disclosed funding: $161M
- Latest round: Series B (Jun 1, 2022)
- Investors on record: 13

## About

Founded in 2020 and based in Pennsylvania, US, Mineralys Therapeutics, Inc. operates as a biopharmaceutical company that provides therapy for patients with hypertension. In February 2024, Mineralys Therapeutics, Inc. raised USD 120 million in PIPE funding co-led by investors TCG Crossover Management and RA Capital Management, with participation from other investors OrbiMed Advisors and Venrock. The firm, as of July 2024, is led by its founder and Executive Chair, BT Slingsby, and CEO, Jon Congleton.

The clinical-stage biopharmaceutical company develops targeted therapies for diseases driven by elevated aldosterone levels. The company prioritizes tackling the substantial medical issue of hypertension, aiming to reduce the economic costs and health implications linked with poorly managed high blood pressure. Mineralys Therapeutics' flagship product, Lorundrostat, is a highly selective aldosterone synthase inhibitor designed to specifically target and reduce elevated aldosterone levels without affecting cortisol, offering a therapeutic approach for patients with aldosterone-dependent hypertension. With clinical results from phase 2 trials demonstrating both efficacy and safety, Mineralys represents a pivotal advancement in hypertension treatment.

The company plans to utilize the February 2024 funding for research and development of lorundrostat, working capital, and general corporate purposes.

## Funding rounds

- Series B, Jun 1, 2022, $118M — Adams Street Partners, Boulder Ventures, HBM Partners, Andera Partners, SR One, Ysios Capital Partners, HealthCor Group, Sectoral Asset Management, RTW Investments, RA Capital Management, Rock Springs Capital, Samsara BioCapital, Catalys Pacific
- Series A, Jan 18, 2022, $3.3M — HBM Partners
- Series A, Feb 17, 2021, $40M — Adams Street Partners, HBM Partners, Samsara BioCapital, Catalys Pacific

## Investors

- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series A, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A, Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B
- Catalys Pacific (https://capitalatlas.ai/funds/catalys-pacific) — Series A, Series B
- Boulder Ventures (https://capitalatlas.ai/funds/boulder-ventures) — Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series B
- HealthCor Group (https://capitalatlas.ai/funds/healthcor-group) — Series B
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Rock Springs Capital — Series B